KRAS and neoplasm: On a biological level, cancers with KRAS G12C and STK11 co-mutations treated with adagrasib were associated with increased tumour infiltrating lymphocytes, suggesting that the drug alters the tumour microenvironment and reverses STK11-induced immunosuppression.